Department of Neurosurgery and California Center for Pituitary Disorders, University of California, San Francisco, California.
J Neurosurg. 2013 Dec;119(6):1478-83. doi: 10.3171/2013.7.JNS13273. Epub 2013 Aug 23.
Syndrome of inappropriate antidiuretic hormone secretion-induced hyponatremia is a common morbidity after pituitary surgery that can be profoundly symptomatic and cause costly readmissions. The authors calculated the frequency of postoperative hyponatremia after 1045 consecutive operations and determined the efficacy of interventions correcting hyponatremia.
The authors performed a retrospective review of 1045 consecutive pituitary surgeries in the first 946 patients treated since forming a dedicated pituitary center 5 years ago. Patients underwent preoperative and daily inpatient sodium checks, with outpatient checks as needed.
Thirty-two patients presented with hyponatremia; 41% of these patients were symptomatic. Postoperative hyponatremia occurred after 165 operations (16%) a mean of 4 days after surgery (range 0-28 days); 19% of operations leading to postoperative hyponatremia were associated with postoperative symptoms (38% involved dizziness and 29% involved nausea/vomiting) and 15% involved readmission for a mean of 5 days (range 1-20 days). In a multivariate analysis including lesion size, age, sex, number of prior pituitary surgeries, surgical approach, pathology, lesion location, and preoperative hypopituitarism, only preoperative hypopituitarism predicted postoperative hyponatremia (p = 0.006). Of patients with preoperative hyponatremia, 59% underwent medical correction preoperatively and 56% had persistent postoperative hyponatremia. The mean correction rates were 0.4 mEq/L/hr (no treatment; n = 112), 0.5 mEq/L/hr (free water restriction; n = 24), 0.7 mEq/L/hr (salt tablets; n = 14), 0.3 mEq/L/hr (3% saline; n = 20), 0.7 mEq/L/hr (intravenous vasopressin receptor antagonist Vaprisol; n = 22), and 1.2 mEq/L/hr (oral vasopressin receptor antagonist tolvaptan; n = 9) (p = 0.002, ANOVA). While some patients received more than 1 treatment, correction rates were only recorded when a treatment was given alone.
After 1045 pituitary operations, postoperative hyponatremia was associated exclusively with preoperative hypopituitarism and was most efficiently managed with oral tolvaptan, with several interventions insignificantly different from no treatment. Promptly identifying hyponatremia in high-risk patients and management with agents like tolvaptan can improve safety and decrease readmission. For readmitted patients with severely symptomatic hyponatremia, the intravenous vasopressin receptor antagonist Vaprisol is another treatment option.
抗利尿激素分泌不当综合征导致的低钠血症是垂体手术后常见的并发症,可导致严重的症状并导致昂贵的再次入院。作者计算了 1045 例连续手术中术后低钠血症的发生率,并确定了纠正低钠血症的干预措施的疗效。
作者对 5 年前成立专门的垂体中心以来治疗的 946 例患者中的 1045 例连续垂体手术进行了回顾性分析。患者接受术前和每日住院期间的钠检查,必要时进行门诊检查。
32 例患者出现低钠血症;其中 41%的患者有症状。术后低钠血症发生在 165 例手术(16%)后,平均术后 4 天(范围 0-28 天);导致术后低钠血症的手术中,19%与术后症状相关(38%涉及头晕,29%涉及恶心/呕吐),15%需要平均住院 5 天(范围 1-20 天)再次入院。在包括病变大小、年龄、性别、垂体手术次数、手术入路、病理、病变部位和术前垂体功能减退的多变量分析中,只有术前垂体功能减退预测术后低钠血症(p=0.006)。术前低钠血症患者中,59%术前接受了药物纠正,56%术后仍存在低钠血症。平均校正率分别为 0.4 mEq/L/hr(未治疗;n=112)、0.5 mEq/L/hr(自由水限制;n=24)、0.7 mEq/L/hr(盐片;n=14)、0.3 mEq/L/hr(3%盐水;n=20)、0.7 mEq/L/hr(静脉血管加压素受体拮抗剂 Vaprisol;n=22)和 1.2 mEq/L/hr(口服血管加压素受体拮抗剂托伐普坦;n=9)(p=0.002,方差分析)。虽然一些患者接受了多种治疗,但仅在单独给予一种治疗时才记录校正率。
在 1045 例垂体手术后,术后低钠血症仅与术前垂体功能减退有关,最有效的治疗方法是口服托伐普坦,几种干预措施与未治疗相比无显著差异。及时识别高危患者的低钠血症并使用托伐普坦等药物治疗可以提高安全性并减少再次入院。对于有严重症状性低钠血症的再次入院患者,静脉血管加压素受体拮抗剂 Vaprisol 是另一种治疗选择。